Treatment of Multiple Myeloma with High-Risk Cytogenetics
Treatment of Multiple Myeloma with High-Risk Cytogenetics
A 55-year-old African-American Woman With Relapsed Multiple Myeloma
August 2015
- A 55-year-old African-American woman presented to her PCP complaining of worsening fatigue, back pain, and bone pain
- PMH: hypertension managed on a beta blocker, mild renal impairment
- Laboratory results:
- Hb, 11.0 g/dL;
- Ca2+, 10.1 mg/dL;
- Creatinine, 1.2 mg/dL;
- M-protein, 0.9 g/dL
- Β2M, 5.0 mg/L
- Albumin, 2.9 g/dL
- MRI showed multiple small lytic lesions in the T1/T2 vertebrae
- Bone marrow biopsy confirmed the diagnosis of multiple myeloma; R-ISS stage II; t(4;14)
- She was treated with lenalidomide/bortezomib/dexamethasone (RVd) for 6 months and achieved a VGPR
- The patient was recommended for autologous transplant, however, she instead opted to continue on a de-escalated treatment regimen of Rd after stating that she struggled to maintain her treatment schedule
May 2018
- M-protein, May 1.5 g/dL
June 2018
- M-protein, 1.7 g/dL
July 2018
- MRI, no new lytic skeletal lesions
- Laboratory results:
- Hb, 11.5 g/dL;
- Ca2+, 9.8 mg/dL;
- Creatinine, 1.1 mg/dL;
- M-protein, 1.9 g/dL
- Β2M, 4.2 mg/L
- ECOG PS: 0
CAR T and CRS Adverse Events Considered in Relapsed Multiple Myeloma
October 24th 2024During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for a patient with relapsed/refractory multiple myeloma and relevance of the KarMMa-3 trial for their treatment.
Read More
Functional High Risk and Bridging in Multiple Myeloma Considered With CAR T Cells
October 9th 2024Samer A. Al'Hadidi, MD, MS, reviewed the benefits of cilta-cel in the subgroup analysis of CARTITUDE-4 in patients with relapsed/refractory multiple myeloma and functional high risk, bridging to cilta-cel, and time to treatment in the second article of a 2-part series.
Read More
Lenalidomide Break Possible? Study Shows Hope for MRD-Negative Myeloma
October 7th 2024A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.
Read More
